21 CFR Part 1271 · Human Cells, Tissues, and Cellular and Tissue-Based Products

§ 1271.180 Procedures

Subpart D - Current Good Tissue Practice Official text on eCFR Amendment history

(a) General. You must establish and maintain procedures appropriate to meet core CGTP requirements for all steps that you perform in the manufacture of HCT/Ps. You must design these procedures to prevent circumstances that increase the risk of the introduction, transmission, or spread of communicable diseases through the use of HCT/Ps.

(b) Review and approval. Before implementation, a responsible person must review and approve these procedures.

(c) Availability. These procedures must be readily available to the personnel in the area where the operations to which they relate are performed, or in a nearby area if such availability is impractical.

(d) Standard procedures. If you adopt current standard procedures from another organization, you must verify that the procedures meet the requirements of this part and are appropriate for your operations.

Independent copy, not an official legal edition. 21 CFR is a U.S. Government work in the public domain; this text comes from the eCFR and the annual CFR edition, and may lag recent amendments. The authoritative version is on ecfr.gov. Compliome is not affiliated with or endorsed by FDA. Not legal advice.

What FDA inspectors cite under § 1271.180

Form FDA 483 observations citing this section, fiscal years 2009–2026 (Human Tissue for Transplantation).

  • Procedures to meet core CTGP 191
  • Review and approval-responsible person 20
  • Availability of procedures 9
  • Design adequate to bar spread of CD's 9
  • Adopted from another organization 8

Warning letters citing § 1271.180

1 FDA warning letters since 2017 cite this section :

FDA guidance that cites § 1271.180

Amendment history

Federal Register documents that created or amended this section.